Anavex Life Sciences Corp. AVXL 深 沪
已收盘 08-14 16:00:00 美东时间
3.22
-0.050
-1.53%
华盛通- 最 高3.27
- 今 开3.25
- 成交量 69.81万股
- 最 低 3.14
- 昨 收 3.27
- 总市值 2.98亿
- 52周最高 10.40
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 2.255
- 委 比 -97.04%
- 总股本 9267.18万
- 历史最高 31.50
- 量 比 0.90
- 振 幅 3.98%
- 历史最低 0.60
- 每 手 1
- 风险率 2.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
Anavex Life Sciences Corp. filed definitive proxy materials with the SEC ahead of its 2026 Annual Meeting, urging stockholders to vote "FOR" its six independent director nominees on the WHITE proxy card. The company highlighted its strategy to enhance long-term value, including advancing oral blarcamesine across three CNS indications (early Alzheimer's disease, Rett syndrome, and Fragile X syndrome) and refreshing the Board with two new independe...
08-11 12:00
Anavex Life Sciences Urges Stockholders To Reject Attempt By PVG Asset Management And Patrick S. Adams To Acquire Control Of The Company
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with Independent Directors Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger and Dr....
08-03 20:07
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Anavex Life Sciences Corp. announced the nomination of two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, to enhance the board with deep life sciences experience. The company urged stockholders to reject PVG Asset Management Corporation and Patrick S. Adams' attempt to acquire control. The refreshed board, including six independent members, aims to advance the company's CNS disease treatments and maximize shareholder valu...
08-03 12:00
Anavex Life Sciences Q2 EPS $(0.06) Beats $(0.08) Estimate
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 53.85 percent increase over losses of $(0.13) per share from the same period last year.
07-30 20:42
Anavex Life Sciences GAAP EPS of -$0.06
Anavex Life Sciences press release (AVXL): Q2 GAAP EPS of -$0.06. Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, compared to $102.6 million as of September 30, 2025. T...
07-30 20:14
Anavex Life Sciences Receives Expected Delinquency Notification From Nasdaq
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it
05-22 20:03
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. (AVXL) received a delinquency notice from Nasdaq on May 20, 2026, for failing to file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). The notice does not immediately affect the company's stock listing. Anavex is working to complete the filing and regain compliance.
05-22 12:00
Anavex Life Sciences Announces COO Departure Amid Restructuring
Anavex Life Sciences ( ($AVXL) ) has provided an announcement. On May 11, 2026,...
05-16 06:01
